Illumina announced that it is filing its second patent infringement lawsuit against Complete Genomics, Inc. The new lawsuit was filed for Complete Genomics’ infringement of U.S. Patent No. 8,192,930, titled “Method for Sequencing a Polynucleotide Template.” This time Illumina is targeting Complete Genomics’ Combinatorial Probe-Anchor Ligation (cPal) read technology.
Complete Genomcis uses a library prep protocol that transforms genomic DNA fragments into repetitive DNA Nano Balls. These DNA Nano Balls are then placed on a special microarray to be sequenced. Complete Genomics then uses ligase-based DNA reading technology or the combinatorial probe-anchor ligation cPAL.
The cPAL and the DNA Nanoarray technologies were first introduced in the 2010 Science paper by Radoje Drmanac et al. Human Genome Sequencing Using Unchained Base Reads on Self-Assembling DNA Nanoarrays. The paper showed off Complete Genomics technology to sequence human genome at low cost.
Earlier in 2010, Illumina filed a law suit against Complete genomics for infringing U.S. Patent No. 6,306,597 on “DNA sequencing by parallel oligonucleotide extensions”. And the law suit is pending in US court now. The new Illumina lawsuit adds to Complete Genomics’ woes of its recent layoff and financial restructuring of complete genomics.
Complete genomics Defends cPAL Technology
Complete Genomics, reacting to Illumina’s lawsuit, announced that it will vigorously defend itself against the patent infringement lawsuit filed by Illumina, Inc. Dr. Clifford A. Reid, Ph.D., Complete’s chairman, president and chief executive officer said that
Despite this move by Illumina, we remain fully committed to the strategy and actions that we recently announced. We will continue to fully service and support our customers while defending against this lawsuit. This is yet another attempt by Illumina to compete in the courtroom instead of the marketplace and reflects the extent to which it sees Complete’s more accurate genome sequencing technology as a competitive threat.
Complete Genomics also added that, Complete considers that Illumina’s earlier suit is also without merit and it has filed for the patent to be declared invalid.